Worldwide, colorectal cancer is the third most common type of cancer affecting both sexes. It has been proposed that a small subset of cancer cells (cancer stem cells) within each tumor is able to initiate tumor growth. In 2007, two research groups simultaneously identified a colon cancer stem cell population in human tumors by the use of CD133 expression. In the present study, we used a human colon cancer cell line, SW620, to analyze the cancer stem cell-like characteristics of CD133 + cells in vitro and in vivo. In vitro, CD133 + SW620 cells had a higher proliferative capacity, were more irradiation-and chemotherapy-resistant, and had a higher expression of β-catenin compared with CD133 − cells. Injections of either CD133 + or CD133 − cells into the skin or rectal mucosa of NOD/SCID mice led to tumors; however, injection of CD133 + cells resulted in the formation of larger tumors. Tumors derived from injections of CD133 − cells did not contain any CD133 + cells, whereas tumors derived from injections of CD133 + cells did contain CD133 + cells, suggesting self-renewing capability. However, the proportion of CD133 + cells in the newly formed tumors in vivo was lower than the proportion of CD133 + cells in vitro. In conclusion, the human colon cancer cell line, SW620, contains both CD133 + and CD133 − phenotypes, and the CD133 + phenotype has characteristics consistent with those of cancer stem cells.
INTRODUCTION
differentiation potential that gives configurationality to cancer tissues, and tumorigenic potential (13,16). The assumption that CSCs are responsible for tumor growth Colorectal cancer (CRC) is the third most common form of cancer and the second leading cause of cancer-was first proven in acute myeloid leukemia by John Dick's group in 1997 (3) . Subsequently, CSCs have related death in the Western world, causing 655,000 deaths worldwide per year (12). Knowledge related to been isolated in solid cancers by their self-renewing activity and daughter cell-producing ability. Al-Hajj's the occurrence, development, and treatment of CRC has been accumulating, and this has been accompanied by group first identified CSCs in solid tumors; they demonstrated that only a small fraction of breast cancer cells remarkable developments in medical treatment. However, radical cures for metastasis and recurrent CRC re-expressing CD44 + CD24 − /low were able to form tumor xenografts and to give rise to both tumorigenic and non-main difficult, and the establishment of strategies for new treatments is expected. In recent years, it has be-tumorigenic cells (1) . In human CRC, two research groups identified a CSC come clear that only a small proportion of cells in cancer tissues have the ability to proliferate. These cells are population by using a cell surface marker, CD133 (15, 17) . CD133 is an antigen that is a 120-kDa five-called cancer stem cells (CSCs) or cancer-initiating cells and are characterized by having a self-renewing ability, transmembrane domain glycoprotein expressed on nor-mal primitive hematopoietic, endothelial, neural, and ep-Biotec). After magnetic sorting, cell purity was evaluated by flow cytometry as described above. ithelial cells (18, 22, 23) . In addition, CD133 is a marker of CSCs in brain tumors, pancreatic cancer, and lung Analysis of Resistance to a Chemotherapeutic Agent cancer (8, 9, 19) .
It is now thought that these CSCs are involved not 5-Fluorouracil (5-FU) was used as a chemotherapeutic agent to analyze the chemotherapy resistance of only in the formation of tumors, but also in metastasis and, moreover, they have resistance against existing SW620 cells. Isolated cells were seeded at 1 × 10 4 cells/ well in a microtiter plate (Becton Dickinson) in a final chemical and irradiation therapies (2, 6, 9, 10) .
Based on such knowledge, CSCs have gained atten-volume of 100 µl of culture medium with either 0, 1, or 10 µg/ml 5-FU per well. After incubation for 48 h, cell tion as targets for new cancer treatments. In this study, we investigated the cancer stem cell-like properties of proliferation was analyzed by an MTS assay as described above. CD133 + cells by evaluating differences from CD133 − cells with respect to irradiation resistance, chemotherapy
Analysis of Resistance to Irradiation resistance, and tumorigenic potential using a human CRC cell line, SW620.
In order to examine the irradiation resistance of SW620 cells, isolated cells were seeded at 1 × 10 4 cells/ MATERIALS AND METHODS well in a microtiter plate (Becton Dickinson) in a final volume of 100 µl of culture medium per well. After in-Cell Culture cubation for 24 h, cells were irradiated at 4 or 6 Gy. A human colon cancer cell line, SW620, was used in After further incubation for 48 h, cell proliferation was the present study. SW620 cells were maintained in highanalyzed by an MTS assay. glucose DMEM medium (Invitrogen) containing 10% fetal bovine serum (Invitrogen), 100 U/ml penicillin G, Analysis of the Expression of a Self-Renewal Gene, and 100 µg/ml of streptomycin (Invitrogen) at 37°C in β-Catenin a 5% humidified CO 2 atmosphere.
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was conducted in SW620 cells to exam-Analysis of Cell Proliferation ine the difference in the expression of a self-renewal Cell-proliferating capacity was routinely examined gene, β-catenin, between CD133 + and CD133 − SW620 during the culture of SW620 cells. Isolated cells were cells. Total RNA was extracted from CD133 + and seeded at 1 × 10 3 cells/well in a 96-well microtiter plate CD133 − cells using TRIzol (Invitrogen) reagent accord-(Microtest Tissue Culture Plate, Becton Dickinson, ing to the manufacturer's instructions. Reverse transcrip-Tokyo, Japan) in a final volume of 100 µl of culture tion was performed at 22°C for 10 min, followed by medium per well. After incubation, cell proliferation 42°C for 20 min, using specific primers with 2.0 µg of was analyzed by an MTS assay (CellTiter-Glo Lumines-RNA per reaction. Primers used were β-catenin, sense cent Cell Viability Assay, Promega, Madison, WI), and 5′-ACTGGCAGCAACAGTCTTACC-3′ and antisense the absorbance at 492 nm was determined by a plate 5′-TTTGAAGGCAGTCTGTCGTAAT-3′, and human reader (Multiskan JX; Thermo Labsystems).
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control, sense 5′-TCCCCATCACCATC CD133 Expression Analysis in SW620 Cells TTCCAG-3′ and antisense 5′-GAGTCCTTCCACGAT Dissociated SW620 cells were stained with anti-ACCAA-3′. Amplification was performed for 27 cycles CD133/2-APC antibody (Miltenyi Biotec, Tokyo, Ja-(25 cycles for GAPDH) for 1 min at 95°C, 1 min at pan), incubated for 10 min at 4°C, and analyzed by a 59.3°C (60°C for GAPDH), and 1 min at 72°C. PCR FACSAria cell-sorting system (Becton Dickinson).
products were resolved on 1% agarose gels and visual-Mouse IgG2b-APC (Miltenyi Biotec) was the isotype ized by ethidium bromide staining. control antibody. Dead cells were eliminated with pro-Animal Experiments pidium iodide.
All animal procedures were approved by the Okay-Magnetic Cell Separation of SW620 Cells ama University Institutional Animal Care and Use Comby CD133 Expression mittee, and thus within the guidelines for human care of laboratory animals. Six-to 8-week-old nonobese/severe SW620 cells were separated by immunomagnetic selection on the basis of CD133 expression. Cells were combined immunodeficiency (NOD/SCID) mice (Charles River Laboratories, Tokyo, Japan) were used in the fol-labeled with CD133/1 microbeads using a Miltenyi Biotec CD133 cell isolation kit according to the manufac-lowing transplantation experiments. The mice were maintained in a central animal facility at Okayama Uni-turer's protocol and separated by autoMACS (Miltenyi versity on a 12-h light/dark cycle, receiving water and colonic obstruction resulting from rectal tumor progression (21) , and cells (5 × 10 4 ) were slowly injected into nutrition ad libitum.
the submucosal space with a 30-gauge needle. Mice Transplantation Experiments were sacrificed at 5 weeks posttransplantation. NOD/SCID mice (6-8 weeks of age) were anaesthe-Histopathological Analyses tized with the use of diethyl ether solution. Purified CD133 + or CD133 − SW620 cells (5 × 10 4 ) were sus-At the time of sacrifice, the developed tumors were removed, fixed in 20% formalin, and embedded in par-pended in a 1:1 mixture of culture medium and Matrigel (BD Biosciences, Tokyo, Japan) and injected subcutane-affin. Serial tissue sections were stained with hematoxylin and eosin (H&E) or examined immunohistochemi-ously into the mice. For submucosal transplantation into the rectum, mice were placed in a supine position, the cally using anti-CD133/1 antibody (Miltenyi Biotec Co., Tokyo, Japan). For immunohistochemical staining, tis-ano-rectal wall was cut at a length of 7 mm to prevent sue sections were processed with an automated immu-39.62% of SW620 cells were CD133 + (Fig. 1B) . After magnetic selection using CD133/1 microbeads, cell pu-nostainer (Ventana XT system BENCHMARK XT, Ventana Japan, Japan) using heat-induced epitope re-rity was evaluated by flow cytometry using CD133/2-APC antibody. The purity was 97.2% in CD133 + cells trieval and standard DAB detection kit (Ventana). Endogenous peroxidase activity was quenched by immer- (Fig. 1C) , and 98.8% in CD133 − cells (Fig. 1D) , indicating that high purity separation was obtained by this pro-sion in 3% hydrogen peroxide for 10 min before automated imunohistochemistry. Ten different sections cedure. were examined for CD133 expression analysis in each Proliferation, Chemotherapy Resistance, group by third-party examiners.
Irradiation Resistance, and Gene Expression Statistical Analyses of CD133 + SW620 Cells Mean values are presented with SDs. Differences be-We examined the in vitro proliferation of CD133 + tween groups were estimated by Student's t-test analyand CD133 − SW620 cells using a MTS assay. As shown sis. All differences were deemed significant at the level in Figure 2A , CD133 + cells proliferated at a higher rate of p < 0.05. than did CD133 − cells. As well, CD133 + cells showed significantly higher proliferation in the presence of both RESULTS 1 and 10 µg/ml 5-FU ( Fig. 2B ) and after 6 Gy irradia-Identification of CD133 Expression in SW620 Cells tion (Fig. 2C) . β-Catenin mRNA expression was detected in both CD133 + and CD133 − SW620 cells by RT-Flow cytometry was used to determine CD133 expression level in SW620 cells. The results showed that PCR analysis. CD133 + cells possessed a higher level of β-catenin expression CD133 − cells (Fig. 2D) , which was transplantation of CD133 − cells showed that there were no CD133 + cells within the tumors. On the other hand, confirmed by real-time PCR analysis. in the tumors developed by transplantation of CD133 + Histopathological Examination of Developed Tumors cells, CD133 + cells were observed within the tumor at a In Vivo proportion of 1.48 ± 0.39% for the subcutaneous site and 4.19 ± 0.62% for the rectal mucosa ( Figs. 4 and 5 ). We examined whether there were differences in the No mice showed metastases at the time of sacrifice. tumor-forming ability of CD133 + and CD133 − SW620 cells when transplanted into subcutaneous or rectal sites DISCUSSION in NOD/SCID mice. Transplantation of both CD133 + In 1997, it was reported that only some leukemia and CD133 − cells led to the formation of tumors comcells have tumorigenic potential, and these could be disposed of poorly differentiated adenocarcinoma (Figs. 3, tinguished by using surface markers (3) . Cells with such 4, and 5). Transplantation of CD133 + cells resulted in characteristics are called cancer stem cells (CSCs), and faster tumor formation and larger tumors in both sites many studies on CSCs have been carried out. Moreover, (Fig. 3) . The tumors formed by CD133 + cell transplant in cases of solid cancer, there have been many reports exhibited more active mitosis of tumor cells, thus reon the identification and separation of CSCs. Regarding flecting the high level of tumorigenic potential. Immuhuman colorectal cancer (CRC), there were two reports nochemical analysis of the tumors that developed from in 2007 on the identification and separation of CSCs isolated parental cells occur to some degree due to the accumulation of DNA methylation and unexpected mu-using CD133 as a marker. These studies found that all cells capable of initiating colon cancer were positive for tations during culture. The major advantage of the use of well-established cell lines allows us to repeat the ex-CD133 and speculated that CD133 is a marker for CSC in CRC (15, 17) . Therefore, in the present study, we used periments and share the data with researchers all over the world. a CRC cell line, SW620, to investigate the CSC-like characteristics of CD133 + cells with regard to in vitro
In vitro, we found that CD133 + SW620 cells exhibited a higher proliferating potential and showed a higher proliferating potential, resistance against 5-FU, resistance against irradiation, and tumor formation in vivo. resistance to 5-FU and irradiation compared with CD133 − cells, which is consistent with the characteris-We found that CD133 + cells existed at a ratio of 39.6% in the human colon cancer cell line, SW620. In tics of CSCs. Other studies have reported mechanisms for the drug and irradiation resistance of CD133 + cells. other studies, the ratios of CD133 + cells in CRC cells were 2.5 ± 1.4% and 8.9-15.9% (15,17). According to Drug-resistance mechanisms include a higher mRNA expression of the antiapoptotic molecules. Breast cancer the previously reported literature on human CRC cell lines, the proportion of CD133 + cells ranged from 99.0% resistance protein 1 (BCRP 1) and O 6 -methylguanine-DNA methyltransferase (MGMT) in CD133 + glioblas-to less than 1%, and therefore the frequency is not constant at all in the studies using cell lines (11). This vari-toma cells (14) and the autocrine effect of interleukin-4, which protects from apoptosis, in freshly obtained hu-ability may be explained by the fact that in established cell lines, changes in the characteristics of the primarily man CRC specimens (20). Irradiation-resistance mecha-nisms include a stronger DNA repair ability in CD133 + In both sites, tumors that developed from transplantation of CD133 + cells contained CD133 + cells, whereas glioblastoma cells compared with CD133 − cells (2).
Next, we examined the in vivo characteristics of no CD133 + cells were observed in the tumors induced by transplantation of CD133 − cells. In the tumors formed CD133 + cells by transplanting them into subcutaneous tissue and rectal submucosa of NOD/SCID mice. For-by transplantation of CD133 + SW620 cells, the frequency of occurrence of CD133 + cells was higher in the mation of tumors was observed after transplantation of both CD133 + and CD133 − cells in both sites; however, rectum compared with the subcutaneous site, suggesting that the rectal mucosa provided a better niche for CSCs. CD133 + cells produced larger tumors, indicating a higher tumorigenic potential. This result is in contrast However, the frequency of CD133 + cells in vivo (1.48-4.19%) was lower than the 39.6% observed in vitro. Un-with those of previous studies in which CD133 − cells isolated from fresh human CRC specimens did not have der in vitro culture conditions, cells receive many stresses such as cell passage, which might favor those tumorigenic potential (15,17). However, our results are consistent with those of Ieta et al., who also reported cells with higher proliferation capacity, resulting in high ratios of CD133 + cells. As well, environmental factors that CD133 − cells in a CRC cell line formed tumors and that CD133 + cells had a higher tumorigenic potential in vivo may affect the behavior of CD133 + cells. Some of this difference may be due to the different assay than CD133 − cells (11). Moreover, there is also a report that CD133 − cells from a glioma cell line (C6) exhibited methods used: flow cytometry for in vitro experiments and immunochemical staining for in vivo experiments. tumorigenic potential and had characteristics similar to CSCs, even though CD133 is considered to be a CSC Ideally, experiments characterizing CSCs in CRC would be best performed using human tumor tissue as a marker in brain cancer (24). 
